Test Price
2,800 AED✅ Home Collection Available
GRHL2 Gene Autosomal Dominant Deafness Type 28 Genetic Test in UAE | AED 2800
Executive Summary & Core Metrics
✅Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 9001:2015 Accredited Processing.
🚚Premium Logistics: Paid Hospital-Grade Home Collection via ISO Certified Cold-Chain Home Collection and VIP Mobile Phlebotomy.
📞Clinical Guidance: Telephonic Post-Test Clinical Guidance in result interpretation.
💳Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731.
Test Overview & Methodology
The GRHL2 Gene Autosomal Dominant Deafness Type 28 NGS Test is a high-precision genetic analysis that identifies pathogenic variants in the GRHL2 gene linked to progressive sensorineural hearing loss. It enables definitive molecular diagnosis, guides clinical management, and informs family planning.
| Feature | Our Test | Closest Alternative |
|---|---|---|
| Precision | Full gene sequencing (NGS), detects all variant types | Single‑gene Sanger sequencing, limited to known variants |
| Methodology | Next‑Generation Sequencing (Illumina® platform) | Capillary electrophoresis (Sanger) |
| Turnaround Time | 3 to 4 Weeks | 6 to 8 Weeks (often) |
| Price (AED) | 2800 | Varies, typically 2500–3500 |
Physician Insight & Safety Protocols
“As a genetic counselor and medical geneticist, I understand that genetic testing for hearing loss carries emotional weight. This test is a powerful diagnostic tool, but results must be interpreted alongside audiological and clinical findings. Our team provides comprehensive genetic counselling to ensure you fully understand the implications for you and your family.”
— Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403
Medication Advisory
⚠️ Do not discontinue prescribed medication without consulting your doctor.
Safety Exclusion & Emergency Red Flags
Exclusion Criteria (Do not proceed with elective test):
- Active middle ear infection, acute ear trauma, or recent ear surgery.
- Individuals unable to provide informed consent; minors without legal guardian consent as per Federal Decree-Law No. 4 of 2016 on Medical Liability.
- Patients currently in acute medical crisis unrelated to hearing loss.
Emergency Red Flags (Seek immediate medical attention):
- Sudden severe hearing loss, especially unilateral, within the last 72 hours.
- Acute vertigo with nausea and vomiting, or sudden tinnitus with neurological signs.
- Do not delay emergency care for genetic testing.
Patient FAQ & Clinical Guidance
1. What is the GRHL2 gene test for?
The GRHL2 gene test detects pathogenic variants causing autosomal dominant non‑syndromic hearing loss (DFNA28) with 99.9% accuracy. It is designed for patients with a family history of early‑onset progressive hearing loss to enable definitive molecular diagnosis, guide clinical management, and inform family planning.
2. How is the sample collected and what is the turnaround time?
Sample collection is a simple blood draw, cheek swab, or one drop of blood on an FTA card; our VIP mobile phlebotomy team brings hospital‑grade cold‑chain logistics to your home across all emirates. After the lab receives your sample, final results are delivered within 3 to 4 weeks.
3. Is this covered by insurance in the UAE?
Most UAE‑based insurance plans cover genetic testing for hearing loss when medically indicated; our dedicated billing team verifies your policy instantly via WhatsApp at +971 54 548 8731 and provides direct billing options. We also offer transparent self‑pay packages to ensure no patient is turned away.
UAE Regulatory & Data Privacy Adherence
This test is performed in compliance with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Clinical testing safety and patient consent adhere to Federal Decree-Law No. 4 of 2016 on Medical Liability.
Clinical & Logistical Metadata
| Parameter | Detail |
|---|---|
| Test Name | GRHL2 Gene Autosomal Dominant Deafness Type 28 Genetic Test |
| Price (AED) | AED 2,800 |
| Turnaround Time | 3–4 weeks |
| Sample Type / Matrix | Whole Blood, Buccal Swab, or Dried Blood Spot (FTA Card) |
| Methodology Used | Next-Generation Sequencing (NGS) on Illumina® Platform |
| ICD-10-CM Code | H90.5 (Sensorineural hearing loss, bilateral) |
| LOINC Code | 21636-6 (GRHL2 gene mutation analysis) |
| DHA Facility License & Laboratory Address | DHA License No. 1143, Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians